[go: up one dir, main page]

WO2007134169A3 - Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof - Google Patents

Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof Download PDF

Info

Publication number
WO2007134169A3
WO2007134169A3 PCT/US2007/068671 US2007068671W WO2007134169A3 WO 2007134169 A3 WO2007134169 A3 WO 2007134169A3 US 2007068671 W US2007068671 W US 2007068671W WO 2007134169 A3 WO2007134169 A3 WO 2007134169A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzolactam
benzimidazole
indole
analogs
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/068671
Other languages
French (fr)
Other versions
WO2007134169A2 (en
WO2007134169A9 (en
Inventor
John R Didsbury
Tatyana Dyakonov
Simon N Haydar
Michael L Jones
Francine F Li
Christopher J Markworth
Jan J Scicinski
Leonard A Cabana
Jessymol Mathew
David N Middlemiss
Glenn C Collupy
Frank J Schoenen
James F Burns
David N Vanvliet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuada LLC
Original Assignee
Nuada LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuada LLC filed Critical Nuada LLC
Publication of WO2007134169A2 publication Critical patent/WO2007134169A2/en
Publication of WO2007134169A9 publication Critical patent/WO2007134169A9/en
Priority to US12/268,237 priority Critical patent/US20090264384A1/en
Anticipated expiration legal-status Critical
Publication of WO2007134169A3 publication Critical patent/WO2007134169A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Benzimidazole, indole and benzolactam boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof.
PCT/US2007/068671 2004-11-01 2007-05-10 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof Ceased WO2007134169A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/268,237 US20090264384A1 (en) 2004-11-01 2008-11-10 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79955906P 2006-05-10 2006-05-10
US60/799,559 2006-05-10

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/038853 Continuation-In-Part WO2006050053A2 (en) 2004-11-01 2005-10-27 Compounds and methods of use thereof
US71827708A Continuation-In-Part 2004-11-01 2008-04-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/268,237 Continuation-In-Part US20090264384A1 (en) 2004-11-01 2008-11-10 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof

Publications (3)

Publication Number Publication Date
WO2007134169A2 WO2007134169A2 (en) 2007-11-22
WO2007134169A9 WO2007134169A9 (en) 2008-07-24
WO2007134169A3 true WO2007134169A3 (en) 2009-02-12

Family

ID=38610879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068671 Ceased WO2007134169A2 (en) 2004-11-01 2007-05-10 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2007134169A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025349T2 (en) 2009-01-23 2016-02-29 Euro Celtique Sa Hydroxamic acid derivatives
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
JP2013536200A (en) 2010-08-20 2013-09-19 アミラ ファーマシューティカルス，インコーポレーテッド Autotaxin inhibitors and uses thereof
US20130196990A1 (en) 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
AR092790A1 (en) 2012-02-01 2015-05-06 Euro Celtique Sa BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
WO2014053968A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
WO2015042052A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Heterocyclic vinyl autotaxin inhibitor compounds
WO2015042053A1 (en) 2013-09-17 2015-03-26 Pharmakea, Inc. Vinyl autotaxin inhibitor compounds
US9850203B2 (en) 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
HRP20210431T1 (en) 2013-11-18 2021-05-14 Forma Therapeutics, Inc. TETRAHYDROQUINOLINE PREPARATIONS AS BETROMODOMENE BETHODOMENE INHIBITORS
RU2720237C2 (en) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Compositions containing benzopiperazine as bromodomain bet inhibitors
PE20160654A1 (en) 2013-11-22 2016-07-15 Pharmakea Inc AUTOTAXIN INHIBITOR COMPOUNDS
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2016055582A1 (en) * 2014-10-08 2016-04-14 Thomas Helledays Stiftelse För Medicinsk Forskning Heterocyclic compounds as dctpp1 modulators
EP4026549A1 (en) 2015-05-27 2022-07-13 Sabre Therapeutics LLC Autotaxin inhibitors and uses thereof
DE102017005091A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one
DE102017005089A1 (en) 2016-05-30 2017-11-30 Bayer Pharma Aktiengesellschaft Substituted 3,4-dihydroquinoxaline-2 (1H) -one
US11266631B2 (en) 2016-10-11 2022-03-08 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
TWI748194B (en) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 Novel lxr modulators with bicyclic core moiety
JP2022522928A (en) 2018-12-18 2022-04-21 ムンディファーマ・インターナショナル・コーポレーション・リミテッド Compounds for treating multiple myeloma
PT3952995T (en) 2019-04-12 2023-10-25 Riboscience Llc Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069337A (en) * 1975-10-21 1978-01-17 Sterling Drug Inc. 2-substituted-indole-1-lower-alkanecarboxamides having anti-secretory or anti-ulcer activity
US4209524A (en) * 1976-03-23 1980-06-24 Laboratoire L. Lafon Acetohydroxamic acids
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US5550143A (en) * 1992-05-25 1996-08-27 Adir Et Compagnie Heterocyclic compounds
EP0737671A2 (en) * 1995-04-10 1996-10-16 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
WO2001045702A1 (en) * 1999-12-21 2001-06-28 Celgene Corporation SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS
WO2001070675A2 (en) * 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002085916A1 (en) * 2001-04-24 2002-10-31 University Of North Carolina At Chapel Hill 9-[(5-dihydroxyboryl)-pentyl] purines, inhibitor of inflammatory cytokines
WO2005051324A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006050236A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050053A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050054A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006077139A2 (en) * 2005-01-21 2006-07-27 Centre National De La Recherche Scientifique Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069337A (en) * 1975-10-21 1978-01-17 Sterling Drug Inc. 2-substituted-indole-1-lower-alkanecarboxamides having anti-secretory or anti-ulcer activity
US4209524A (en) * 1976-03-23 1980-06-24 Laboratoire L. Lafon Acetohydroxamic acids
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US5550143A (en) * 1992-05-25 1996-08-27 Adir Et Compagnie Heterocyclic compounds
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
EP0737671A2 (en) * 1995-04-10 1996-10-16 Takeda Chemical Industries, Ltd. Aromatic hydroxamic acid compounds, their production and use
WO2001045702A1 (en) * 1999-12-21 2001-06-28 Celgene Corporation SUBSTITUTED ACYLHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS
WO2001070675A2 (en) * 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002085916A1 (en) * 2001-04-24 2002-10-31 University Of North Carolina At Chapel Hill 9-[(5-dihydroxyboryl)-pentyl] purines, inhibitor of inflammatory cytokines
WO2005051324A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006050236A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050053A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006050054A2 (en) * 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
WO2006077139A2 (en) * 2005-01-21 2006-07-27 Centre National De La Recherche Scientifique Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. S. GÜNES ET. AL.: "Synthesis of Some Hydroxamic Acid derivatives of Benzimidazole and their Antibscterial and Antifungal Activities", ARZNEIMITTEL FORSCHUNG, vol. 42, 1992, pages 1045 - 1048, XP001537627 *
J. M. SALVINO ET. AL.: "Solid-Phase Synthesis of an Arylsulfone Hydroxamate Library.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 10, 2000, pages 1637 - 1640, XP002504588 *
S. KAFKA ET. AL.: "Hydroboration of 1-allyl-1,2,3,4-tetrahydroquinoline", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, vol. 50, 1985, pages 1194 - 1200, XP009108858 *

Also Published As

Publication number Publication date
WO2007134169A2 (en) 2007-11-22
WO2007134169A9 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2007134169A3 (en) Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
WO2006050236A3 (en) Compounds and methods of use thereof
ZA200703111B (en) New modified release tablet formulations for proton pump inhibitors
SG171649A1 (en) Dpp iv inhibitor formulations
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
GB2459393B (en) Novel capsule formulation for the proton pump inhibitor omeprazole
IL180872A0 (en) Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
HUS1400008I1 (en) Administration of dipeptidyl peptidase inhibitors
IL182696A0 (en) New modified release pellet formulations for proton pump inhibitors
MX2009011588A (en) Solid dosage forms.
CA2672094C (en) Methods and apparatus for identifying subject matter in view data
PL2247602T3 (en) Adamantyl o-glucuronide derivatives as inhibitors of dipeptidyl peptidase iv for the treatment of diabetes
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
IL192403A0 (en) Fgf-receptor (fgfr)agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof
DE502007005902D1 (en) -METHYL-19-NOR-20-SPIROX-4-EN-3-ONE), as well as the PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF
IL182054A0 (en) Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
EP2062579A4 (en) Solid pharmaceutical composition for oral administration comprising optically stable ramosetron
WO2006050053A3 (en) Compounds and methods of use thereof
WO2006050054A3 (en) Compounds and methods of use thereof
WO2006002077A3 (en) Stable pharmaceutical formulations of benzimidazole compounds
WO2009076234A3 (en) Synthesis methods of histone deacetylase inhibitors (hdacis)
IT1401284B1 (en) NEW PHARMACEUTICAL FORMULATIONS SUITABLE FOR ORAL ADMINISTRATION OF DIHYDRATE ESOMEPRAZOLE MAGNESIUM, IN THE FORM OF MUPS TABLETS (MULTI UNIT PELLETS SYSTEM).
ATE479427T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING CANDESARTAN-CILEXETIL
WO2012072977A8 (en) Formulations comprising methylthioninium chloride
WO2011042890A3 (en) Use of phenolic compounds for protein deglycolysation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07797411

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07797411

Country of ref document: EP

Kind code of ref document: A2